Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
Cosmo Pharmaceuticals has appointed Andrea Cherubini as Chief AI Officer, marking a strategic move to integrate AI across its portfolio. Cherubini, who previously served as Senior Vice President - Science, AI, and Data since 2018, was instrumental in developing GI Genius™, the first AI-powered polyp detection system in gastroenterology.
In his new role, Cherubini will expand AI applications beyond endoscopy into multiple areas including:
- Gastroenterology pipeline, focusing on Bile Acid Diarrhea (BAD)
- Dermatology pipeline, optimizing clinical trials for Breezula®
- Drug discovery and development
CEO Giovanni Di Napoli emphasized AI's role as a core growth pillar, while Cherubini expressed commitment to advancing AI-driven healthcare solutions across drug development, diagnostics, and personalized medicine.
Cosmo Pharmaceuticals ha nominato Andrea Cherubini come Chief AI Officer, segnando una mossa strategica per integrare l'IA nel suo portafoglio. Cherubini, che in precedenza ha ricoperto il ruolo di Vicepresidente Senior - Scienza, IA e Dati dal 2018, è stato fondamentale per lo sviluppo di GI Genius™, il primo sistema di rilevamento dei polipi alimentato da IA in gastroenterologia.
Nella sua nuova funzione, Cherubini espanderà le applicazioni dell'IA oltre l'endoscopia in diverse aree, tra cui:
- Il settore gastroenterologico, con un focus sulla Diarrea da Acidi Biliari (BAD)
- Il settore dermatologico, ottimizzando le sperimentazioni cliniche per Breezula®
- Scoperta e sviluppo di farmaci
Il CEO Giovanni Di Napoli ha sottolineato il ruolo dell'IA come un pilastro fondamentale per la crescita, mentre Cherubini ha espresso l'impegno a promuovere soluzioni sanitarie basate sull'IA in tutto lo sviluppo di farmaci, diagnostica e medicina personalizzata.
Cosmo Pharmaceuticals ha nombrado a Andrea Cherubini como Chief AI Officer, marcando un movimiento estratégico para integrar la IA en su portafolio. Cherubini, quien previamente se desempeñó como Vicepresidente Senior - Ciencia, IA y Datos desde 2018, fue fundamental en el desarrollo de GI Genius™, el primer sistema de detección de pólipos impulsado por IA en gastroenterología.
En su nuevo rol, Cherubini expandirá las aplicaciones de IA más allá de la endoscopia en múltiples áreas, incluyendo:
- El pipeline de gastroenterología, centrado en la Diarrea por Ácidos Biliares (BAD)
- El pipeline de dermatología, optimizando ensayos clínicos para Breezula®
- Descubrimiento y desarrollo de medicamentos
El CEO Giovanni Di Napoli enfatizó el papel de la IA como un pilar central de crecimiento, mientras que Cherubini expresó su compromiso de avanzar en soluciones de salud impulsadas por IA en desarrollo de fármacos, diagnóstico y medicina personalizada.
Cosmo Pharmaceuticals는 AI 최고 책임자(Chief AI Officer)로 Andrea Cherubini를 임명하며 포트폴리오 전반에 AI를 통합하기 위한 전략적 움직임을 취했습니다. Cherubini는 2018년부터 과학, AI 및 데이터의 수석 부사장으로 재직하며 소화기 내시경에서 첫 번째 AI 기반 용종 탐지 시스템인 GI Genius™의 개발에 기여했습니다.
그의 새로운 역할에서 Cherubini는 내시경을 넘어 여러 분야에서 AI 응용 프로그램을 확장할 예정입니다. 포함되는 분야는:
- 담즙산 설사를 중심으로 하는 위장관 분야
- Breezula®에 대한 임상 시험 최적화를 목표로 하는 피부과 분야
- 약물 발견 및 개발
CEO Giovanni Di Napoli는 IA가 핵심 성장 기둥이 되는 역할을 강조했으며, Cherubini는 약물 개발, 진단 및 맞춤형 의료 전반에 걸쳐 AI 기반 건강 관리 솔루션을 발전시키겠다는 의지를 밝혔습니다.
Cosmo Pharmaceuticals a nommé Andrea Cherubini au poste de Chief AI Officer, marquant un mouvement stratégique pour intégrer l'IA dans son portefeuille. Cherubini, qui a précédemment occupé le poste de Vice-Président Senior - Science, IA et Données depuis 2018, a joué un rôle clé dans le développement de GI Genius™, le premier système de détection de polypes alimenté par IA en gastro-entérologie.
Dans son nouveau rôle, Cherubini étendra les applications de l'IA au-delà de l'endoscopie dans plusieurs domaines, notamment :
- Le domaine de la gastro-entérologie, axé sur la Diarrhée par Acides Biliaires (BAD)
- Le domaine de la dermatologie, optimisant les essais cliniques pour Breezula®
- La découverte et le développement de médicaments
Le PDG Giovanni Di Napoli a souligné le rôle de l'IA en tant que pilier central de croissance, tandis que Cherubini a exprimé son engagement à faire progresser les solutions de santé pilotées par l'IA dans le développement de médicaments, le diagnostic et la médecine personnalisée.
Cosmo Pharmaceuticals hat Andrea Cherubini zum Chief AI Officer ernannt, was einen strategischen Schritt zur Integration von KI in sein Portfolio darstellt. Cherubini, der zuvor seit 2018 als Senior Vice President - Wissenschaft, KI und Daten tätig war, spielte eine entscheidende Rolle bei der Entwicklung von GI Genius™, dem ersten KI-gestützten System zur Erkennung von Polypen in der Gastroenterologie.
In seiner neuen Rolle wird Cherubini die Anwendungen von KI über die Endoskopie hinaus in mehrere Bereiche erweitern, darunter:
- Den gastroenterologischen Bereich, mit Fokus auf die Diarrhö durch Gallensäuren (BAD)
- Den dermatologischen Bereich, Optimierung klinischer Studien für Breezula®
- Arzneimittelentdeckung und -entwicklung
CEO Giovanni Di Napoli betonte die Rolle von KI als zentralen Wachstumsfaktor, während Cherubini sein Engagement bekräftigte, KI-gesteuerte Gesundheitslösungen in der Arzneimittelentwicklung, Diagnostik und personalisierten Medizin voranzutreiben.
- Strategic expansion of AI capabilities across multiple business segments
- Appointment of experienced internal leader with proven track record in AI implementation
- Integration of AI into drug development and clinical trials could improve R&D efficiency
- None.
Dublin, Ireland--(Newsfile Corp. - February 11, 2025) - Planet Friendly Technologies, Inc.Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team.
Andrea has been pivotal in the development and commercialization of Cosmo’s GI Genius™, the world’s first AI-powered polyp detection system in gastroenterology. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications.
AI as a Strategic Growth Driver
In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo’s entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others:
- Gastroenterology Pipeline – Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders.
- Dermatology Pipeline – Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula® and other dermatological innovations.
- AI-Enabled Drug Discovery & Development – Expanding AI’s role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo’s position as a leader in AI-driven healthcare solutions.
At the same time, Andrea will continue to play a critical role in shaping Cosmo’s Intelligent Medical Devices division’s AI roadmap, reinforcing GI Genius™ as the leading real-time AI platform in endoscopy.
Giovanni Di Napoli, CEO of Cosmo, commented: “AI is no longer simply an enabler — it is a core pillar of Cosmo’s growth strategy. Andrea has already demonstrated his ability to bring AI-powered innovations to market with GI Genius™, and now, as Chief AI Officer, he will lead our AI expansion across the entire organization. We have the expertise, the infrastructure, and the vision to take AI beyond endoscopy and into new frontiers, creating significant value for both patients and shareholders.”
Andrea Cherubini, Chief AI Officer, added: “I am honoured to take on this new role at such an exciting time for Cosmo. AI is transforming healthcare, and we are just scratching the surface of its potential. By embedding AI into drug development, diagnostics, and personalized medicine, we can drive real impact. I look forward to working with our talented teams to bring AI-driven solutions to more areas of our portfolio and deliver meaningful advancements in patient care.”
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Events
| 2024 Full-Year Results (unaudited) | March 6, 2025 |
| J.P. Morgan European Opportunities Forum, London | March 12, 2025 |
| 2024 Annual Report Publication | March 20, 2025 |
| 26th Kepler Cheuvreux Swiss Seminar, Zurich | March 20, 2025 |
| Life Sciences Conference, Amsterdam | April 2-3, 2025 |
| 2025 Half-Year Results and Report | July 23, 2025 |
For further information, please contact:
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Attachments
250211_Cosmo Pharma_Media Release_Chief AI Officer_EN_Final
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240391
FAQ
What is the strategic impact of Andrea Cherubini's appointment as Chief AI Officer for CMOPF?
How will AI integration affect CMOPF's drug development pipeline?
What is Andrea Cherubini's track record with CMOPF before becoming Chief AI Officer?
How does CMOPF plan to implement AI in its dermatology division?
